Quick Answer
CITIUS ONCOLOGY, INC. reported R&D Expense of $6.42 million for fiscal year 2025.
CITIUS ONCOLOGY, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $6.42M | +30.3% |
| 2024 | $4.93M | +16.1% |
| 2023 | $4.24M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $1.02M | -19.5% | +8.5% |
| June 30, 2025 | $938.3K | -17.1% | -70.1% |
| March 31, 2025 | $3.14M | +132.7% | +148.3% |
| December 31, 2024 | $1.26M | +10.1% | +11.8% |
| June 30, 2024 | $1.13M | — | -16.1% |
| March 31, 2024 | $1.35M | — | +17.5% |
| December 31, 2023 | $1.15M | — | — |
- CITIUS ONCOLOGY, INC. showed an increase of +30.3% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, CITIUS ONCOLOGY, INC.’s r&d expense has grown by 51.4% (from $4.24 million to $6.42 million).
- The most recent figure is from CITIUS ONCOLOGY, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: